Lung Cancer

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

Isabel Preeshagul, DO, MBS, discusses considerations for treatment selection in the first and second line for patients with EGFR-mutated NSCLC.

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.

Nicolas Girard, MD, discusses PROs from the LUMINOSITY trial of Teliso-V in patients with c-Met protein–overexpressing, EGFR wild-type, nonsquamous NSCLC.

Treatment with Deltacel was safe and showed antitumor activity at 10 months in a patient with stage IV metastatic non–small cell lung cancer.

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

Shirish M. Gadgeel, MD, on long-term follow-up data from MARIPOSA for amivantamab plus lazertinib in first-line EGFR-mutated non–small cell lung cancer.

Jacob Sands, MD, discusses consolidation therapy durvalumab as a new standard of care in limited-stage small cell lung cancer.

Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.

The FDA approved osimertinib for EGFR-mutated, locally advanced, unresectable, non–small cell lung cancer after chemoradiation.

Charu Aggarwal, MD, MPH, FASCO, on data for CAN-2409 plus valacyclovir with continued immune checkpoint inhibitors in advanced non–small cell lung cancer.

BDTX-1535 yielded durable clinical activity in patients with relapsed/refractory, EGFR-mutant NSCLC harboring resistance mutations.

The CHMP has recommended the European approval of serplulimab for the first-line treatment of extensive-stage small cell lung cancer.

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

In research published in Nicotine & Tobacco Research, lead author Charnita Zeigler-Johnson, PhD, MPH, Associate Director of Community Outreach and Engagement, studied the prevalence of smoking stigma among the African American/Black community.

The FDA has approved amivantamab plus chemotherapy for locally advanced or metastatic NSCLC harboring select EGFR mutations after an EGFR TKI.

Experts across the lung cancer treatment space impart their key takeaways from research shared at the 2024 IASLC World Conference on Lung Cancer.

Andrea Wolf, MD, MPH, discusses challenges in conducting randomized controlled trials to assess the role of surgery in the treatment of mesothelioma.

The FDA has approved frontline pembrolizumab plus chemotherapy for use in unresectable advanced or metastatic malignant pleural mesothelioma.

Shirish M. Gadgeel, MD, discusses long-term follow-up data from the MARIPOSA study for patients with EGFR-positive advanced non–small cell lung cancer.

Nagashree Seetharamu, MD, MBBS, discusses currently utilized platforms and workflows for molecular testing in lung cancer at Northwell Health.